Chronic benzodiazepine use in general practice patients with depression: An evaluation of controlled treatment and taper-off: Report on behalf of the Dutch Chronic Benzodiazepine Working Group
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Many patients with depression take benzodiazepine drugs long term despite the absence of continuing therapeutic value. Aims: To evaluate a treatment programme involving gradual discontinuation with or without simultaneous selective serotonin reuptake inhibitor (SSRI) prescribing and to determine the long-term outcome after benzodiazepine withdrawal. Method: Patients went through three phases – change to an equivalent dose of diazepam; subsequent randomisation to either 20 mg of paroxetine or placebo; and gradual reduction of diazepam in depression-free patients – with a follow-up after 2 or 3 years. Results: A total of 230 patients were recruited and 75% in the paroxetine group and 61% in the placebo group were successfully treated after 6 weeks (P=0.067). After 2 or 3 years 13% of patients were still benzodiazepine free: 26% of those who had successfully tapered off benzodiazepine and 6% of the total group. Conclusions: Transfer to diazepam followed by gradual withdrawal is an effective way of discontinuing chronic benzodiazepine use. The addition of SSRI treatment is of limited value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
The benzodiazepine withdrawal symptom questionnaire
Tyrer, P., Murphy, S., & Riley, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90009-w · Cited by 188
Murphy, S. M., & Tyrer, P. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.511 · Cited by 104
Long-term benzodiazepine users 3 years after participation in a discontinuation program
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.757 · Cited by 87
Cited by
The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods
Penninx, B. W. J. H., Beekman, A. T. F., Smit, J. H., Zitman, F. G., Nolen, W. A., Spinhoven, P., Cuijpers, P., De Jong, P. J., Van Marwijk, H. W. J., Assendelft, W. J. J., et al. (2008) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.256 · Cited by 927
Self-citationBenzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“In both groups depressive ratings improved with no significant effect of paroxetine, but paroxetine did have a beneficial effect on anxiety symptoms (Zitman and Couvée, 2001) (Ib).”
BackgroundWithdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar, R. C. O., Couvée, J. E., Van Balkom, A. J. L. M., Mulder, P. G. H., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.189.3.213 · Cited by 205
Self-citationLemoine, P., Kermadi, I., Garcia-Acosta, S., Garay, R. P., & Dib, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.015 · Cited by 180
Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., Van Den Hoogen, J. M., & Zitman, F. G. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.498 · Cited by 154
Self-citationPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Ng, B. J., Le Couteur, D. G., & Hilmer, S. N. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0544-4 · Cited by 118
“Medications trialled include switching to long half-life BZDs such as diazepam or lormetazepam [43, 96]; antidepressants such as paroxetine [95, 135], imipramine [136] and trazodone [96]; hypnotics such as melatonin [93, 137]; b-blockers; and antiepileptics such as carbamazepine [138] and pregabalin [139].”
BackgroundFluyau, D., Revadigar, N., & Manobianco, B. E. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317753340 · Cited by 109
Gorgels, W. J. M. J., Oude Voshaar, R. C., Mol, A. J. J., van de Lisdonk, E. H., van Balkom, A. J. L. M., van den Hoogen, H. J. M., Mulder, J., Breteler, M. H. M., & Zitman, F. G. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.09.001 · Cited by 100
Self-citationRisk versus risk: a review of benzodiazepine reduction in older adults
Paquin, A. M., Zimmerman, K., & Rudolph, J. L. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.925444 · Cited by 82
“Among the 28 studies in our analysis, prior BZD dose was a conflicting predictor of success [38,41].”
BackgroundWithdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Withdrawal from long-term benzodiazepine use: randomised trial in family practice.
(2006) · PubMed Central · Cited by 67
Ten Wolde, G. B., Dijkstra, A., Van Empelen, P., Van Den Hout, W., Knuistingh Neven, A., & Zitman, F. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02141.x · Cited by 52
Self-citationDiscontinuation of Long-Term Benzodiazepine Use: 10-Year Follow-Up
de Gier, N., Gorgels, W., Lucassen, P., Oude Voshaar, R., Mulder, J., & Zitman, F. (2011) · Family Practice · doi:10.1093/fampra/cmq113 · Cited by 43
Soni, A., Thiyagarajan, A., & Reeve, J. (2023) · Addiction · doi:10.1111/add.15997 · Cited by 41
Is Melatonin Helpful in Stopping the Long-Term Use of Hypnotics? A Discontinuation Trial
Vissers, F. H. J. A., Knipschild, P. G., & Crebolder, H. F. J. M. (2007) · Pharmacy World & Science · doi:10.1007/s11096-007-9118-y · Cited by 36
Review: Adjunctive pharmacologic approaches for benzodiazepine tapers
Welsh, J. W., Tretyak, V., McHugh, R. K., Weiss, R. D., & Bogunovic, O. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.028 · Cited by 31
Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications
Baldwin, D. S. (2022) · Addiction · doi:10.1111/add.15695 · Cited by 28
The Long-Term Outcome of a Benzodiazepine Discontinuation Programme in Depressed Outpatients
Couvée, J. E., Timmermans, M. A. Y., & Zitman, F. G. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00330-5 · Cited by 20
Self-citationLong-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review
Danborg, P. B., Valdersdorf, M., & Gøtzsche, P. C. (2019) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-180046 · Cited by 14
“The median intervention period was 15 weeks (range 7 to 32 weeks), and the median follow-up after the randomised phase was 52 weeks (range 24 to 364 weeks) for 11 trials; the remaining trial [38] accepted varying follow-up periods ranging from four to 211 weeks).”
BackgroundInfluentialGarel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01689-y · Cited by 13
Metadata
- Authors
- Zitman, F. G., & Couvée, J. E.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2001-04
- Volume
- 178
- Issue
- 4
- Pages
- 317-324
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W1978296118
- Cited by
- 90
- References
- 5
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.